BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37166562)

  • 21. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
    Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J
    Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with Alzheimer's Disease Have Increased Levels of Insulin-like Growth Factor-I in Serum but not in Cerebrospinal Fluid.
    Horvath A; Salman Z; Quinlan P; Wallin A; Svensson J
    J Alzheimers Dis; 2020; 75(1):289-298. PubMed ID: 32250294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Åhman HB; Giedraitis V; Cedervall Y; Lennhed B; Berglund L; McKee K; Kilander L; Rosendahl E; Ingelsson M; Åberg AC
    J Alzheimers Dis; 2019; 71(s1):S75-S83. PubMed ID: 31104024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.
    Laske C; Stransky E; Fritsche A; Eschweiler GW; Leyhe T
    Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):80-5. PubMed ID: 18806919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations between Alzheimer's disease biomarkers and postoperative delirium or cognitive dysfunction: A meta-analysis and trial sequential analysis of prospective clinical trials.
    Geng J; Zhang Y; Chen H; Shi H; Wu Z; Chen J; Luo F
    Eur J Anaesthesiol; 2024 Mar; 41(3):234-244. PubMed ID: 38038408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium.
    Hov KR; Bolstad N; Idland AV; Zetterberg H; Blennow K; Chaudhry FA; Frihagen F; Ræder J; Wyller TB; Watne LO
    Dement Geriatr Cogn Dis Extra; 2017; 7(3):374-385. PubMed ID: 29282410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes mellitus contributes to higher cerebrospinal fluid tau levels selectively in Alzheimer's disease patients with the APOE4 genotype.
    Motta C; Assogna M; Bonomi CG; Mascolo AP; De Lucia V; Semprini R; Mercuri NB; Koch G; Martorana A
    Eur J Neurol; 2021 Dec; 28(12):3965-3971. PubMed ID: 34309155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.
    Osorio RS; Ayappa I; Mantua J; Gumb T; Varga A; Mooney AM; Burschtin OE; Taxin Z; During E; Spector N; Biagioni M; Pirraglia E; Lau H; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Rapoport DM; de Leon MJ
    Neurobiol Aging; 2014 Jun; 35(6):1318-24. PubMed ID: 24439479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concordance of Alzheimer's Disease-Related Biomarkers Between Intraventricular and Lumbar Cerebrospinal Fluid in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H; Vanninen A; Tesseur I; Pemberton D; Van Der Ark P; Kokkola T; Herukka SK; Rauramaa T; Hiltunen M; Blennow K; Zetterberg H; Leinonen V
    J Alzheimers Dis; 2023; 91(1):305-319. PubMed ID: 36404546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid beta 1-42 and tau in the cerebrospinal fluid of renal failure patients for the diagnosis of Alzheimer's disease.
    Shea YF; Chu LW; Mok MY; Lam MF
    J Nephrol; 2014 Apr; 27(2):217-20. PubMed ID: 24473733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
    Geijselaers SLC; Aalten P; Ramakers IHGB; De Deyn PP; Heijboer AC; Koek HL; OldeRikkert MGM; Papma JM; Reesink FE; Smits LL; Stehouwer CDA; Teunissen CE; Verhey FRJ; van der Flier WM; Biessels GJ;
    J Alzheimers Dis; 2018; 61(1):309-320. PubMed ID: 29154275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
    Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum.
    Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL
    J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.